Chemotherapy and Cetuximab in Patients Undergoing Surgery for Peritoneal Carcinomatosis From Colorectal Cancer

Inclusion Criteria

• •DISEASE CHARACTERISTICS:
• •Histologically confirmed colorectal adenocarcinoma meeting the following criteria:
• •* Exclusively peritoneal carcinomatosis (no other metastases)
• •* Resectable disease
• •Primary tumor may be same in the same location as another synchronous carcinomatosis
• •Patients with metastatic disease who have been in complete remission for more than 1 year are eligible regardless of prior chemotherapy
• •PATIENT CHARACTERISTICS:
• •WHO performance status 0-2
• •Life expectancy ≥ 12 weeks
• •ANC ≥ 1.5 x 10\^9/L
• •Platelet count ≥ 100 x 10\^9/L
• •Hemoglobin ≥ 10 g/dL
• •Bilirubin ≤ 1.25 times upper limit of normal (ULN)
• •AST and ALT ≤ 3 times ULN
• •Creatinine ≤ 1.25 times ULN
• •Creatinine clearance ≥ 30 mL/min
• •Not pregnant or nursing
• •Fertile patients must use effective contraception
• •No allergy, hypersensitivity, or other contraindication to leucovorin calcium, oxaliplatin, or fluorouracil
• •No other noncancerous disease that would preclude study therapy
• •Good nutritional status
• •No sensitive peripheral neuropathy with functional impairment
• •No hypoplasia or bone marrow failure
• •No clinically significant cardiovascular disease within the past year (e.g., unstable angina or myocardial infarction)
• •No other cancer within the past 5 years unless in complete remission with the exception of cervical carcinoma in situ or basal cell cancer
• •No patients deprived of liberty or under supervision
• •No psychological, social, familial, or geographical reasons prohibiting follow-up
• •PRIOR CONCURRENT THERAPY:
• •See Disease Characteristics
• •At least 1 year since prior adjuvant chemotherapy, including prior therapy with oxaliplatin and/or cetuximab
• •No prophylactic phenytoin (Dihydan®, Dilantin®)
• •No prior yellow fever vaccine
• •More than 1 month since participation in another study